Abstract
Neuropathy is the most common and earliest to occur among a variety of vascular complications of diabetes. In contrast to its popularity, it seems that attention has not been sufficiently paid to this complication. This may have been ascribed to the difficulty in understanding of the pathophysiology of neuropathy or lack of effective treatment regimen due in part to the complicated etiology. Nevertheless, there are slow but steady advances in clinical management of diabetic neuropathy involving the proposal of diagnostic criteria or clinical staging of neuropathy for an early detection of nerve deficits and direction of the treatment. Emergence of pain-relieving agents has also contributed to the improvement of quality of life in patients with symptomatic neuropathy. Notwithstanding, there still needs clarification of the pathogenesis for the development of diabetic neuropathy, clinical indices for nerve deficits, and for the prediction of prognosis. In this communication, recent progress in the pathogenesis of diabetic neuropathy will be summarized and its underlying pathology will be introduced.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Dyck PJ, Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. J Neuropathol Exp Neurol. 1996;55(12):1181–93.
Smith AG, Russell J, Feldman EL, Goldstein J, Peltier A, Smith S, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29(6):1294–9.
Arimura A, Deguchi T, Sugimoto K, Uto T, Nakamura T, Arimura Y, et al. Intraepidermal nerve fiber density and nerve conduction study parameters correlate with clinical staging of diabetic polyneuropathy. Diabetes Res Clin Pract. 2013;99(1):24–9.
Tavakoli M, Mitu-Pretorian M, Petropoulos IN, Fadavi H, Asghar O, Alam U, et al. Corneal confocal microscopy detects early nerve regeneration in diabetic neuropathy after simultaneous pancreas and kidney transplantation. Diabetes. 2013;62(1):254–60. doi:10.2337/db12-0574.
Low PA, Lagerlund TD, McManis PG. Nerve blood flow and oxygen delivery in normal, diabetic, and ischemic neuropathy. Int Rev Neurobiol. 1989;31:355–438.
Malik RA. The pathology of human diabetic neuropathy. Diabetes. 1997;46(Suppl 2):S50–3.
Yagihashi S. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes Metab Rev. 1995;11(3):193–225.
Malik RA, Veves A, Walker D, Siddique I, Lye RH, Schady W, et al. Sural nerve fibre pathology in diabetic patients with mild neuropathy: relationship to pain, quantitative sensory testing and peripheral nerve electrophysiology. Acta Neuropathol. 2001;101(4):367–74.
Muller KA, Ryals JM, Feldman EL, Wright DE. Abnormal muscle spindle innervation and large-fiber neuropathy in diabetic mice. Diabetes. 2008;57(6):1693–701.
Decorps J, Saumet JL, Sommer P, Sigaudo-Roussel D, Fromy B. Effect of ageing on tactile transduction processes. Ageing Res Rev. 2014;13:90–9.
Schmidt RE. Neuropathology and pathogenesis of diabetic autonomic neuropathy. Int Rev Neurobiol. 2002;50:257–92.
Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al.; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341–50.
Vincent AM, Hinder LM, Pop-Busui R, Feldman EL. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst. 2009;14(4):257–67.
Yagihashi S, Mizukami H, Sugimoto K. Mechanism of diabetic neuropathy: where are we now and where to go? J Diabetes Investig. 2011;2(1):18–32.
Fernyhough P. Mitochondrial dysfunction in diabetic neuropathy: a series of unfortunate metabolic events. Curr Diab Rep. 2015;15(11):89. doi:10.1007/s11892-015-0671-9.
Beirowski B, Babetto E, Golden JP, Chen YJ, Yang K, Gross RW, et al. Metabolic regulator LKB1 is crucial for Schwann cell-mediated axon maintenance. Nat Neurosci. 2014;17(10):1351–61.
Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care. 2006;29(7):1538–44.
Bierhaus A, Fleming T, Stoyanov S, Leffler A, Babes A, Neacsu C, et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med. 2012;18(6):926–33.
Thornalley PJ. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol. 2002;50:37–57.
Yamamoto Y, Yamamoto H. Controlling the receptor for advanced glycation end-products to conquer diabetic vascular complications. J Diabetes Investig. 2012;3(2):107–14.
Wada R, Yagihashi S. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann N Y Acad Sci. 2005;1043:598–604.
Haslbeck KM, Schleicher E, Bierhaus A, Nawroth P, Haslbeck M, Neundörfer B, et al. The AGE/RAGE/NF-κB pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). Exp Clin Endocrinol Diabetes. 2005;113(5):288–91.
Juranek JK, Geddis MS, Song F, Zhang J, Garcia J, Rosario R, et al. RAGE deficiency improves postinjury sciatic nerve regeneration in type 1 diabetic mice. Diabetes. 2013;62(3):931–43.
Nishizawa Y, Wada R, Baba M, Takeuchi M, Hanyu-Itabashi C, Yagihashi S. Neuropathy induced by exogenously administered advanced glycation end-products in rats. J Diabetes Investig. 2010;1(1–2):40–9.
Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes. 1992;41(1):47–52.
Yamagishi S, Uehara K, Otsuki S, Yagihashi S. Differential influence of increased polyol pathway on protein kinase C expressions between endoneurial and epineurial tissues in diabetic mice. J Neurochem. 2003;87(2):497–507.
Slawson C, Copeland RJ, Hart GW. O-GlcNAc signaling: a metabolic link between diabetes and cancer? Trends Biochem Sci. 2010;35(10):547–55.
Lim JG, Lee JJ, Park SH, Park JH, Kim SJ, Cho HC, et al. Glucagon-like peptide-1 protects NSC-34 motor neurons against glucosamine through Epac-mediated glucose uptake enhancement. Neurosci Lett. 2010;479(1):13–7.
Pop-Busui R, Ang L, Holmes C, Gallagher K, Feldman EL. Inflammation as a therapeutic target for diabetic neuropathies. Curr Diab Rep. 2016;16(3):29. doi:10.1007/s11892-016-0727-5.
Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015;20:658–66.
Acknowledgment
The authors greatly acknowledge previous collaborators who conducted studies cited in this review. Our research was supported by grants in aid from the Ministry of Health and Welfare and the Ministry of Education, Culture, Sports, Science and Technology, Japan.
DOI: There is no duality of interest for the authors.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Yagihashi, S., Mizukami, H. (2018). Diabetic Neuropathy. In: Yamagishi, Si. (eds) Diabetes and Aging-related Complications. Springer, Singapore. https://doi.org/10.1007/978-981-10-4376-5_3
Download citation
DOI: https://doi.org/10.1007/978-981-10-4376-5_3
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-4375-8
Online ISBN: 978-981-10-4376-5
eBook Packages: MedicineMedicine (R0)